Biofilm Formation and Antifungal Resistance in Candida Species

Biofilm Formation and Antifungal Resistance in Candida Species: A Comparative Study of Albicans and Non Albicans Strains in Hematology ICU.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202511581363830

Enrollment

250

Registered

2025-11-24

Start date

2025-11-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

candida infection

Interventions

taking blood and sputum samples

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligible participants in the study were those with invasive infection and had one or more of this criteria : oSuppressed general body immunity. oSuppressed local body immunity as a result of trauma or invasive procedures. oResistant to antibiotic therapy. oNegative samples for bacterial examination and culture. oCritical life threatening infections.

Exclusion criteria

Exclusion criteria: oPatients who received antifungal therapy within 3 days prior to sample collection. oResistant to antibiotic therapy.

Design outcomes

Primary

Measure	Time frame
the prevalence of different candida species including candida auris as the causative agent in hematology ICU infection .	—

Secondary

Measure	Time frame
the prevalence of biofilm formation and biofilm forming genes among different candida species	—

Countries

Egypt

Contacts

Public Contactasmaa salah

doctor

asmaashaltout@aun.edu.eg0201001655790

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026